LivaNova plc (LIVN) Misses Q1 EPS by 10c, Revenues Miss; Updated FY20 EPS Guidance Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St futures gain on tech rebound, Middle East peace hopes
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil falls as traders digest escalation in US-Iran strikes
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
- UBS sees generational semiconductor boom, highlights stock winners
Livanova (LIVN) PT Lowered to $65 at Piper Sandler
April 29, 2020 3:39 PM EDTPiper Sandler analyst Matt O'Brien lowered the price target on Livanova (NASDAQ: LIVN) to $65.00 (from $80.00) while maintaining an Overweight rating.
negative commentary and outlook but lots value trapped in the stock... MoreLivaNova plc (LIVN) Bi-Flow Cannula Receives CE Mark for ECMO Applications
April 27, 2020 9:07 AM EDTLivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today announced its Bi-Flow Extracorporeal Membrane Oxygenation (ECMO) cannula earned CE Mark approval for ECMO procedures where femoral artery cannulation can be applied. Bi-Flow previously received CE Mark in 2019 for cardiac surgery procedures requiring femoral artery cannulation. Now validated for up to 29 days of use, Bi-Flow ECMO is designed to reduce the risk of limb ischemia for patients receiving ECMO and it allows for safe, easy and reproducible procedures.
After witnessing the potential of Bi-Flow in the cardiac surgery setting, the... More
